ImmunityBio announced that the FDA has approved Anktiva plus Bacillus Calmette-Guerin, or BCG, for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer, or NMIBC, with carcinoma in situ, or CIS, with or without papillary tumors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX: